Dyadic International (NASDAQ:DYAI) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Thursday, ValuEngine reports.
Other equities analysts also recently issued research reports about the company. Noble Financial restated a “buy” rating and issued a $9.00 target price on shares of Dyadic International in a research note on Monday, July 8th. TheStreet raised shares of Dyadic International from a “d” rating to a “c” rating in a report on Wednesday, April 17th.
Shares of NASDAQ DYAI traded up $0.02 during midday trading on Thursday, reaching $6.13. The company’s stock had a trading volume of 85,792 shares, compared to its average volume of 62,539. Dyadic International has a 12-month low of $1.40 and a 12-month high of $7.30.
Dyadic International (NASDAQ:DYAI) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.08) earnings per share for the quarter. The firm had revenue of $0.40 million during the quarter. On average, analysts forecast that Dyadic International will post -0.3 EPS for the current fiscal year.
In related news, VP Ronen Tchelet sold 10,000 shares of Dyadic International stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $5.87, for a total value of $58,700.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 23.90% of the company’s stock.
A hedge fund recently bought a new stake in Dyadic International stock. NEXT Financial Group Inc bought a new stake in shares of Dyadic International, Inc (NASDAQ:DYAI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 8,000 shares of the biotechnology company’s stock, valued at approximately $50,000. 0.08% of the stock is currently owned by institutional investors.
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
Read More: What are no-load funds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.